loading
Foghorn Therapeutics Inc stock is traded at $7.92, with a volume of 1,796. It is up +3.05% in the last 24 hours and up +12.03% over the past month. Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$7.86
Open:
$8
24h Volume:
1,796
Relative Volume:
0.01
Market Cap:
$436.96M
Revenue:
$34.16M
Net Income/Loss:
$-98.43M
P/E Ratio:
-2.8905
EPS:
-2.74
Net Cash Flow:
$-119.33M
1W Performance:
-7.95%
1M Performance:
+12.03%
6M Performance:
+30.23%
1Y Performance:
+97.08%
1-Day Range:
Value
$7.98
$8.2451
1-Week Range:
Value
$7.33
$8.79
52-Week Range:
Value
$2.70
$10.25

Foghorn Therapeutics Inc Stock (FHTX) Company Profile

Name
Name
Foghorn Therapeutics Inc
Name
Phone
617-586-3100
Name
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Name
Employee
116
Name
Twitter
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
FHTX's Discussions on Twitter

Compare FHTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
FHTX 7.98 436.96M 34.16M -98.43M -119.33M -2.74
VRTX 447.51 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.90 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.12 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.75 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.52 24.49B 3.30B -501.07M 1.03B 11.54

Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-28-23 Initiated BofA Securities Buy
Jan-05-23 Initiated BMO Capital Markets Outperform
Nov-22-21 Initiated H.C. Wainwright Buy
Nov-17-20 Initiated Cowen Outperform
Nov-17-20 Initiated Goldman Buy
Nov-17-20 Initiated Morgan Stanley Overweight
Nov-17-20 Initiated Wedbush Outperform
View All

Foghorn Therapeutics Inc Stock (FHTX) Latest News

pulisher
Nov 19, 2024

(FHTX) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 19, 2024
pulisher
Nov 12, 2024

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - The Manila Times

Nov 12, 2024
pulisher
Nov 08, 2024

(FHTX) Trading Report - Stock Traders Daily

Nov 08, 2024
pulisher
Nov 08, 2024

What is HC Wainwright’s Estimate for FHTX FY2024 Earnings? - Defense World

Nov 08, 2024
pulisher
Nov 08, 2024

Wedbush Lifts Earnings Estimates for Foghorn Therapeutics - Defense World

Nov 08, 2024
pulisher
Nov 07, 2024

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think - Simply Wall St

Nov 07, 2024
pulisher
Nov 07, 2024

Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter Report - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

Research Analysts Issue Forecasts for FHTX FY2024 Earnings - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

HC Wainwright Has Bullish Estimate for FHTX FY2024 Earnings - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth Carefully - Yahoo Finance

Nov 06, 2024
pulisher
Nov 06, 2024

Foghorn Therapeutics Inc (FHTX) Q3 2024 Earnings: Revenue Surpas - GuruFocus.com

Nov 06, 2024
pulisher
Nov 05, 2024

Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates - MSN

Nov 05, 2024
pulisher
Nov 04, 2024

Foghorn Therapeutics Reports Third Quarter Highlights - TipRanks

Nov 04, 2024
pulisher
Nov 04, 2024

Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update - GlobeNewswire

Nov 04, 2024
pulisher
Oct 27, 2024

(FHTX) Investment Report - Stock Traders Daily

Oct 27, 2024
pulisher
Oct 26, 2024

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Sold by Raymond James & Associates - Defense World

Oct 26, 2024
pulisher
Oct 22, 2024

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk - Simply Wall St

Oct 22, 2024
pulisher
Oct 17, 2024

Short Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Increases By 9.1% - MarketBeat

Oct 17, 2024
pulisher
Oct 16, 2024

Long Term Trading Analysis for (FHTX) - Stock Traders Daily

Oct 16, 2024
pulisher
Oct 11, 2024

Foghorn Therapeutics Unveils Clinical Pipeline Progress - Yahoo Finance

Oct 11, 2024
pulisher
Oct 10, 2024

Foghorn Therapeutics Announces First Patient Dosed with - GlobeNewswire

Oct 10, 2024
pulisher
Oct 10, 2024

Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors - The Manila Times

Oct 10, 2024
pulisher
Oct 10, 2024

Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective - The Bakersfield Californian

Oct 10, 2024
pulisher
Oct 09, 2024

FHTXFoghorn Therapeutics Inc. Latest Stock News & Market Updates - StockTitan

Oct 09, 2024
pulisher
Oct 07, 2024

BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last? - Yahoo Finance

Oct 07, 2024
pulisher
Oct 01, 2024

Foghorn Therapeutics to Participate in the BMO Oncology Summit - GlobeNewswire

Oct 01, 2024
pulisher
Sep 30, 2024

Perceptive Advisors LLC Purchases Shares of 544,000 Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Sep 30, 2024
pulisher
Sep 30, 2024

Perceptive Advisors LLC Buys New Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

Foghorn Therapeutics' SWOT analysis: chromatin biology pioneer's stock outlook By Investing.com - Investing.com UK

Sep 30, 2024
pulisher
Sep 29, 2024

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock Holdings Increased by Rhumbline Advisers - Defense World

Sep 29, 2024
pulisher
Sep 26, 2024

Deerfield Management Company L.P. Series C Takes Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - MarketBeat

Sep 26, 2024
pulisher
Sep 26, 2024

Deerfield Management Company L.P. Series C Purchases Shares of 2,518,500 Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Sep 26, 2024
pulisher
Sep 25, 2024

Foghorn Therapeutics exec sells over $360k in company stock By Investing.com - Investing.com South Africa

Sep 25, 2024
pulisher
Sep 25, 2024

Bank of New York Mellon Corp Buys 18,664 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

Foghorn Therapeutics exec sells over $360k in company stock - Investing.com India

Sep 25, 2024
pulisher
Sep 25, 2024

(FHTX) Long Term Investment Analysis - Stock Traders Daily

Sep 25, 2024
pulisher
Sep 24, 2024

Foghorn Therapeutics (FHTX) Stock Forecast and Price Target 2024 - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase - Benzinga

Sep 24, 2024
pulisher
Sep 24, 2024

Foghorn Therapeutics (NASDAQ:FHTX) Price Target Raised to $9.00 - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

Market Insight: Foghorn Therapeutics Inc (FHTX)’s Notable Gain, Closing at 9.99 - The Dwinnex

Sep 23, 2024
pulisher
Sep 21, 2024

Foghorn Therapeutics exec sells over $116k in company stock By Investing.com - Investing.com Australia

Sep 21, 2024
pulisher
Sep 20, 2024

Foghorn Therapeutics exec sells over $116k in company stock - Investing.com India

Sep 20, 2024
pulisher
Sep 18, 2024

Foghorn Therapeutics executive sells over $107k in company stock By Investing.com - Investing.com Australia

Sep 18, 2024
pulisher
Sep 18, 2024

Foghorn Therapeutics executive sells over $107k in company stock - Investing.com India

Sep 18, 2024
pulisher
Sep 16, 2024

Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength? - MSN

Sep 16, 2024

Foghorn Therapeutics Inc Stock (FHTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):